Aviragen Therapeutics Inc Stock Nasdaq
Stocks
US0537611024
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 145M 126M 117M 108M 204M 13.81B 205M 1.38B 539M 6.88B 544M 532M 22.84B | P/E 2026 * |
-3.08x | P/E 2027 * | -0.6x |
|---|---|---|---|---|---|
| Enterprise Value | 145M 126M 117M 108M 204M 13.81B 205M 1.38B 539M 6.88B 544M 532M 22.84B | EV / Sales 2026 * |
0.72x | EV / Sales 2027 * | 61.6x |
| Free-Float |
98.3% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Aviragen Therapeutics Inc
| 1 day | -8.47% |
| Manager | Title | Age | Since |
|---|---|---|---|
Steven Lo
CEO | Chief Executive Officer | 60 | 2024-03-17 |
Sean Tucker
CTO | Chief Tech/Sci/R&D Officer | 59 | 2024-02-29 |
Jeroen Grasman
DFI | Director of Finance/CFO | - | 2025-05-18 |
| Director | Title | Age | Since |
|---|---|---|---|
David Wheadon
BRD | Director/Board Member | 68 | 2021-04-20 |
William Watson
BRD | Director/Board Member | 76 | 2022-08-03 |
Elaine Heron
BRD | Director/Board Member | 79 | 2021-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.47% | +1,187.88% | - | - | 142M | |
| +10.00% | +13.39% | +51.99% | +83.45% | 56.7B | |
| +0.80% | -7.82% | +24.61% | +60.00% | 51.97B | |
| -0.98% | +0.29% | -14.90% | -14.35% | 23.33B | |
| +0.30% | -5.71% | -9.15% | +345.82% | 21.34B | |
| +1.73% | -1.57% | +35.40% | -28.62% | 17.44B | |
| +4.29% | +1.67% | +201.24% | +344.48% | 14.77B | |
| +1.71% | +0.34% | +50.30% | +169.75% | 13.84B | |
| +4.16% | +4.75% | +462.40% | +177.20% | 12.12B | |
| +5.30% | -7.93% | +67.97% | +162.62% | 11.14B | |
| Average | +1.88% | -0.63% | +96.65% | +144.48% | 24.74B | |
| Weighted average by Cap. | +3.67% | +0.44% | +64.36% | +115.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 200M 174M 162M 149M 282M 19.12B 284M 1.91B 746M 9.53B 753M 736M 31.62B | 2.35M 2.04M 1.9M 1.75M 3.31M 224M 3.33M 22.36M 8.75M 112M 8.83M 8.63M 371M |
| Net income | -24.4M -21.17M -19.75M -18.15M -34.32M -2.33B -34.62M -232M -90.87M -1.16B -91.66M -89.63M -3.85B | -266M -231M -215M -198M -374M -25.39B -378M -2.53B -991M -12.66B -1B -978M -41.99B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
